SCHEMBL90917

SCHEMBL90917

Cc1ccc(S(=O)(=O)OC([C@H]2CC[C@H](NS(=O)(=O)C(C)(C)C)CC2)C(Cl)(Cl)Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
CYP3A4 P08684 2/20 0.39
TSHR P16473 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.35
NPY5R Q15761 1/20 0.33
MMP13 P45452 1/20 0.32
CYP2C19 P33261 1/20 0.32
CYP2D6 P10635 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
CYP1A2 P05177 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
DRD2 P14416 2/20 0.32
ADRA1D P25100 2/20 0.32
ADRA1A P35348 2/20 0.32
ADRA1B P35368 2/20 0.32
ENPP3 O14638 1/20 0.31
ENPP1 P22413 1/20 0.31
ENPP2 Q13822 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5437406 0.83 ALDH1A1 (0.46) ALDH1A1CYP3A4TSHRCYP2D6CYP1A2
SCHEMBL10279957 0.83 ALDH1A1 (0.46) ALDH1A1CYP3A4TSHRCYP2D6CYP1A2
SCHEMBL336360 0.73 CYP2D6 (0.40) ALDH1A1CYP3A4TSHRCYP2C19CYP2D6
SCHEMBL4574789 0.71 ALDH1A1 (0.40) ALDH1A1CYP3A4TSHRL3MBTL1CYP2D6
SCHEMBL9638209 0.70 HTT (0.36) ALDH1A1CYP3A4TSHRCYP2C19CYP2D6
SCHEMBL3454507 0.68 CYP2D6 (0.44) ALDH1A1CYP3A4TSHRCYP2D6CYP1A2
SCHEMBL90959 0.68 NPY5R (0.36) NPY5R
SCHEMBL4578793 0.66 ALDH1A1 (0.49) ALDH1A1CYP3A4TSHRCYP2D6CYP1A2
SCHEMBL14780181 0.66 TSHR (0.45) ALDH1A1CYP3A4TSHRL3MBTL1CYP2D6
SCHEMBL24360805 0.66 POLB (0.43) ALDH1A1CYP3A4TSHRENPP3ENPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299066-B2 Compounds having NPY Y5 receptor antagonistic activity SHIONOGI & CO., LTD. (JP) 2012-10-30 US disclosed
US-20120130070-A1 COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-05-24 US disclosed
US-8129372-B2 Compounds having NPY Y5 receptor antagonistic activity SHIONOGI & CO., LTD. (JP) 2012-03-06 US disclosed
US-20110028468-A1 COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY Shinonogi & Co., Ltd (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120130070-A1 COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY NPY5R, NPY1R, NPY2R ALDH1A1 4801/4885CYP3A4 2582/4885TSHR 90/4885
US-20110028468-A1 COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY NPY5R, NPY1R, NPY2R ALDH1A1 4801/4885CYP3A4 2582/4885TSHR 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.